Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Mantel

Showing results (111-120 of 284) with videos related to

Pageof 29
Sort By:
Pharmacoepidemiology and Drug Safety|November 22, 2016
Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatmentEvans L Sagwa, Patrick C Souverein, Inês Ribeiro, et al.
Pharmacoeconomics|October 5, 2024
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their SuitabilityMarcelien H E Callenbach, Rick A Vreman, Christine Leopold, et al.
Journal of Pharmaceutical Policy and Practice|January 11, 2024
Evaluation of alignment of the reimbursement medicines list for children in Albania with the WHO essential medicines list for childrenE Petro, V Perumal-Pillay, A K Mantel-Teeuwisse, et al.
International Journal of Environmental Research and Public Health|November 13, 2020
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility AnalysisRick A Vreman, Thomas F Broekhoff, Hubert Gm Leufkens, et al.
Drug Safety|March 23, 2011
Today's challenges in pharmacovigilance: what can we learn from epoetins?Hans C Ebbers, Aukje K Mantel-Teeuwisse, Ellen H M Moors, et al.
BMC Public Health|December 20, 2018
The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative studyTom G Jacobs, H Hilda Ampadu, Jarno Hoekman, et al.
Journal of Pharmaceutical Policy and Practice|April 26, 2014
National medicines policies - a review of the evolution and development processesJoëlle M Hoebert, Liset van Dijk, Aukje K Mantel-Teeuwisse, et al.
British Journal of Clinical Pharmacology|August 26, 2004
Recent trends in (under)treatment of hypercholesterolaemia in the NetherlandsAukje K Mantel-Teeuwisse, W M Monique Verschuren, Olaf H Klungel, et al.
Journal of Pain and Symptom Management|May 28, 2013
Consensus building on access to controlled medicines: a four-stage Delphi consensus procedureSaskia Jünger, Sarah Brearley, Sheila Payne, et al.
Health Policy (Amsterdam, Netherlands)|March 23, 2022
A critical review of methodologies used in pharmaceutical pricing policy analysesIris R Joosse, David Tordrup, Lisa Bero, et al.
Pageof 29

Showing results (111-120 of 284) with videos related to

Sort By:
Pageof 29
Pharmacoepidemiology and Drug Safety|November 22, 2016
Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatmentEvans L Sagwa, Patrick C Souverein, Inês Ribeiro, et al.
Pharmacoeconomics|October 5, 2024
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their SuitabilityMarcelien H E Callenbach, Rick A Vreman, Christine Leopold, et al.
Journal of Pharmaceutical Policy and Practice|January 11, 2024
Evaluation of alignment of the reimbursement medicines list for children in Albania with the WHO essential medicines list for childrenE Petro, V Perumal-Pillay, A K Mantel-Teeuwisse, et al.
International Journal of Environmental Research and Public Health|November 13, 2020
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility AnalysisRick A Vreman, Thomas F Broekhoff, Hubert Gm Leufkens, et al.
Drug Safety|March 23, 2011
Today's challenges in pharmacovigilance: what can we learn from epoetins?Hans C Ebbers, Aukje K Mantel-Teeuwisse, Ellen H M Moors, et al.
BMC Public Health|December 20, 2018
The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative studyTom G Jacobs, H Hilda Ampadu, Jarno Hoekman, et al.
Journal of Pharmaceutical Policy and Practice|April 26, 2014
National medicines policies - a review of the evolution and development processesJoëlle M Hoebert, Liset van Dijk, Aukje K Mantel-Teeuwisse, et al.
British Journal of Clinical Pharmacology|August 26, 2004
Recent trends in (under)treatment of hypercholesterolaemia in the NetherlandsAukje K Mantel-Teeuwisse, W M Monique Verschuren, Olaf H Klungel, et al.
Journal of Pain and Symptom Management|May 28, 2013
Consensus building on access to controlled medicines: a four-stage Delphi consensus procedureSaskia Jünger, Sarah Brearley, Sheila Payne, et al.
Health Policy (Amsterdam, Netherlands)|March 23, 2022
A critical review of methodologies used in pharmaceutical pricing policy analysesIris R Joosse, David Tordrup, Lisa Bero, et al.
Pageof 29